Pancreatic cancer remains the third-leading cause of cancer-related death in the U.S., behind lung and colorectal cancers. It is predicted to become the second leading cause before 2030. 

This cancer type can develop with few noticeable symptoms in its early stages and is often diagnosed after it has progressed. 

For researchers, this creates an important need for well-characterized patient-derived biospecimens to identify disease-associated biomarkers, understand tumor biology, and investigate treatment-related changes.

At Bay Biosciences, we provide well-characterized human biospecimens, including pancreatic cancer plasma samples, serum samples, whole blood, and other relevant samples needed to support pancreatic cancer research, biomarker studies, drug development, and translational oncology.

Understanding Pancreatic Cancer

Pancreatic cancer begins when abnormal cells develop in the pancreas and grow uncontrollably. The pancreas is located behind the stomach and performs important functions related to digestion and blood glucose regulation.

Pancreatic cancers differ according to their cell of origin and molecular characteristics. PDAC, which stands for pancreatic ductal adenocarcinoma, accounts for the majority of pancreatic cancers, while pancreatic neuroendocrine tumors represent a smaller group with different biological and clinical features.

Researchers continue to investigate the molecular alterations that contribute to pancreatic tumor development. 

Symptoms

Early pancreatic cancer rarely causes clear warning signs. When symptoms appear, they are often vague and easily mistaken for common digestive or back problems. The most frequently reported ones include:

Diagnosis

Diagnosis usually combines a clinical assessment, imaging, laboratory tests, and a tissue sample.

Physical examination and history:

A doctor reviews symptoms, family history, and risk factors, and checks for jaundice or an enlarged gallbladder or liver.

Imaging:

  • CT scan: typically the first-line test. A specialized pancreas-protocol CT shows the tumor, nearby blood vessels, and any spread to the liver or lymph nodes.
  • MRI and MRCP: these give detailed views of soft tissue and the bile and pancreatic ducts, and help characterize cysts or small lesions.
  • Endoscopic ultrasound (EUS): a thin, flexible tube with an ultrasound probe is passed through the mouth to the stomach, where it can image the pancreas closely. It is particularly good at detecting small tumors.
  • PET scan: sometimes used to look for spread elsewhere in the body.

Biopsy:

Confirmation requires a tissue sample. This is most often collected using fine-needle aspiration or biopsy guided by EUS. A pathologist examines the cells to confirm cancer and its type. In some cases, particularly when a tumor looks clearly removable, surgery may proceed without a prior biopsy.

Blood tests:

Liver function tests can show bile duct obstruction. The tumor marker CA 19-9 may be elevated, but it is not reliable enough to diagnose or screen for pancreatic cancer. Doctors mainly use it to monitor treatment response.

Staging and genetic testing:

Imaging results determine the stage and whether the tumor is resectable, borderline resectable, locally advanced, or metastatic. Genetic testing of the tumor or the patient may guide treatment choices and identify inherited risk for relatives.

Causes

The exact cause of pancreatic cancer is not fully understood, but it arises from accumulated DNA damage in pancreatic cells. 

Mutations in the KRAS gene appear in the vast majority of cases, and they often combine with changes in tumor suppressor genes such as CDKN2A, TP53, and SMAD4. These changes disrupt normal controls on cell growth and division.

Researchers believe many tumors develop from microscopic precursor lesions. These include pancreatic intraepithelial neoplasia (PanIN) and certain cysts such as intraductal papillary mucinous neoplasms (IPMNs). 

Over years, these lesions can accumulate further mutations and progress to invasive cancer. 

Chronic inflammation of the pancreas may also contribute by creating an environment that favors abnormal cell growth.

Risk Factors

A risk factor raises the chance of developing a disease but does not guarantee it. Many people with pancreatic cancer have no obvious risk factors. 

Some common risk factors include: 

Treatment and Research Considerations

Treatment for pancreatic cancer depends on factors such as tumor location, stage, whether the tumor can be surgically removed, and the patient’s overall clinical circumstances.

Treatment may include surgery, chemotherapy, radiation therapy, or combinations of these approaches. Targeted therapies and immunotherapies are also being investigated for selected patients and disease settings.

Because pancreatic cancer can behave differently between patients, researchers continue to investigate molecular features that may help explain differences in treatment response.

Patient-derived Pancreatic Cancer Biospecimens can support these studies by providing biological material for molecular characterization and biomarker investigation.

Pancreatic Cancer Blood Samples

Blood provides a minimally invasive source of biological material for research. Pancreatic Cancer Blood Samples can contain circulating molecules released by tumors or produced in response to disease.

Researchers may analyze blood-derived specimens to investigate:

  • Circulating tumor DNA
  • Cell-free DNA
  • Protein biomarkers
  • Tumor-associated molecules
  • Extracellular vesicles
  • Immune and inflammatory markers
  • Treatment-associated molecular changes
  • Potential indicators of disease progression

Pancreatic Cancer Serum Samples

Pancreatic Cancer Serum Samples are another important resource for biomarker research. Serum is obtained after blood coagulates and is commonly analyzed for proteins, metabolites, antibodies, and other circulating factors.

Researchers can compare serum from pancreatic cancer patients with appropriate control or disease-comparison groups to investigate potential differences associated with malignancy.

Pancreatic Cancer Plasma Samples

Plasma is the liquid component of blood that remains after cells and clotting processes are separated. Pancreatic Cancer Plasma Samples can be used for a range of molecular and biomarker investigations. Researchers may investigate plasma for:

  • Cell-free DNA
  • Circulating tumor DNA
  • Proteins
  • Metabolites
  • Extracellular vesicles
  • Circulating RNA
  • Other potential cancer-associated biomarkers

Frequently Asked Questions

What is the difference between pancreatic cancer plasma and serum?

Plasma is obtained from anticoagulated blood and retains clotting-related components, while serum is collected after blood has clotted. The two specimen types can contain different biological components and may therefore be selected according to the requirements of a particular research assay.

Can serum and plasma be used together in pancreatic cancer research?

Yes. Using both Pancreatic Cancer Serum Samples and Pancreatic Cancer Plasma Samples can provide complementary information, depending on the research objectives and analytical methods.

What are the research applications of Pancreatic Cancer Plasma Samples? 

Researchers may use Pancreatic Cancer Plasma Samples for pancreatic cancer biomarker discovery, early-detection research, liquid biopsy development, treatment-response studies, disease-monitoring research, etc. 

Are research samples ethically sourced?

Yes. All biospecimens available on our website are sourced with ethical guidelines in mind. 

Supporting Your Research with Bay Biosciences

Bay Biosciences is a provider of human biospecimens for pharmaceutical companies, biotechnology organizations, academic institutions, and diagnostic developers. 

Our wide range of specimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.